Clerk of the House of Representatives
Legislative Resource Center
135 Cannon Building
Washington, DC 20515
http://lobbyingdisclosure.house.gov 		Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510
http://www.senate.gov/lobby
LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Organization/Lobbying Firm Self Employed Individual
American Society of Hematology

2. Address

Address1
2021 L Street NW, Suite 900
 Address2
​
City
WASHINGTON
 State
DC
 Zip Code
20036
 Country
USA

3. Principal place of business (if different than line 2)

City
​
State
​
Zip Code
​
Country
​
4a. Contact Name b. Telephone Number c. E-mail
​Ms.
​Suzanne M. Leous
​2027760544
​sleous@hematology.org
5. Senate ID#
​59171-12
7. Client Name Self Check if client is a state or local government or instrumentality
​American Society of Hematology
6. House ID#
​352060000
TYPE OF REPORT 8. Year
​2019
 Q1 (1/1 - 3/31) Q2 (4/1 - 6/30) Q3 (7/1 - 9/30) Q4 (10/1 - 12/31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report Termination Date
​
11. No Lobbying Issue Activity
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13
12. Lobbying 13. Organizations
INCOME relating to lobbying activities for this reporting period was: EXPENSE relating to lobbying activities for this reporting period were:
Less than $5,000
Less than $5,000
$5,000 or more $
​
$5,000 or more $
​30,000.00
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options.
Method A. Reporting amounts using LDA definitions only

Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code

Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

Signature
Digitally Signed By: Suzanne M. Leous
 Date
10/18/2019 9:34:51 AM

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code BUD

16. Specific lobbying issues

Public health program funding

Federal research funding

FY 2020 NIH funding

FY 2020 funding for CDC Sickle Cell Disease Data Collection Program

FY 2020 Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act (H.R. 2740)

H.Amdt.283 to H.R. 2740 (increases funding to the Birth Defects, Development Disabilities, Disabilities and Health account by $2 million and decreases the administration account in the Office of the Secretary of Health and Human Services account by a similar amount)

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Disease Control & Prevention (CDC), Health & Human Services - Dept of (HHS), Natl Institutes of Health (NIH)

18. Name of each individual who acted as a lobbyist in this issue area

First Name Last Name Suffix Covered Official Position (if applicable) New
Tracy
Roades
​
​
Stephanie
Kaplan
​
​
Suzanne
Leous
MPA
​
Leslie
Brady
MPH
​

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MED

16. Specific lobbying issues

Sickle cell disease/trait issues

Hematology/oncology treatment issues

General hematology public health and research issues

NRC training and experience requirements for radiopharmaceuticals

Fetal tissue research

Reauthorization of the Patient-Centered Outcomes Research Institute (PCORI)

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Natl Institutes of Health (NIH), Nuclear Regulatory Commission (NRC)

18. Name of each individual who acted as a lobbyist in this issue area

First Name Last Name Suffix Covered Official Position (if applicable) New
Tracy
Roades
​
​
Suzanne
Leous
MPA
​
Stephanie
Kaplan
​
​
Leslie
Brady
MPH
​

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

Patient Access to Cellular Transplant (PACT) Act (S. 1268/H.R. 2498)

Coverage of blood transfusions under Medicare Hospice Benefit

Reimbursement for CAR-T/cellular and gene therapies

Implementation of the Medicare Access and CHIP Reauthorization Act of 2015 (P.L. 114-10)

Implementation of Patient Protection and Affordable Care Act (P.L. 111-148)

CMS national coverage determinations

Medicaid coverage for sickle cell disease

Issues impacting opioid access/use for patients with hematologic diseases and disorders

Impact of lowering poverty line on access to Medicaid and CHIP

Improving Seniors Timely Access to Care Act of 2019 (H.R. 3107)

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB)

18. Name of each individual who acted as a lobbyist in this issue area

First Name Last Name Suffix Covered Official Position (if applicable) New
Suzanne
Leous
MPA
​
Tracy
Roades
​
​
Stephanie
Kaplan
​
​
Leslie
Brady
MPH
​

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

Cancer Drug Parity Act (S.741 / H.R.1730)

Resident Physician Shortage Reduction Act of 2019 (S. 348/H.R. 1763)

Newborn Screening Saves Lives Reauthorization Act of 2019 (H.R. 2507)

House resolution calling for sickle cell trait research, surveillance, and public education and awareness, and for other purposes (H.Res. 606)

Implementation of Patient Protection and Affordable Care Act (P.L. 111-148)

Hematology and oncology drug research and approval issues

Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144)

Clinical trials regulations and coverage

Issues impacting coverage for hematologic diseases and conditions

Reimbursement for CAR-T/cellular and gene therapies

Issues impacting opioid access/use for patients with hematologic diseases and disorders

NRC training and experience requirements for radiopharmaceuticals

Impact of lowering poverty line on access to Medicaid and CHIP

Reauthorization of the Patient-Centered Outcomes Research Institute (PCORI)

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA), Natl Institutes of Health (NIH), Centers For Medicare and Medicaid Services (CMS), Centers For Disease Control & Prevention (CDC), Nuclear Regulatory Commission (NRC), Office of Management & Budget (OMB)

18. Name of each individual who acted as a lobbyist in this issue area

First Name Last Name Suffix Covered Official Position (if applicable) New
Suzanne
Leous
MPA
​
Tracy
Roades
​
​
Stephanie
Kaplan
​
​
Leslie
Brady
MPH
​

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

Address
​
City
​
State
​
Zip Code
​
Country
​

21. Client new principal place of business (if different than line 20)

City
​
State
​
Zip Code
​
Country
​

22. New General description of client’s business or activities

​

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

First Name
Last Name
Suffix
First Name
Last Name
Suffix
1
​
​
​
3
​
​
​
2
​
​
​
4
​
​
​

ISSUE UPDATE

24. General lobbying issue that no longer pertains

​
​
​
​
​
​
​
​
​

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

Name Address Principal Place of Business
(city and state or country)
Street Address
City State/Province Zip Country
City
State Country

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

1 2 3

FOREIGN ENTITIES

27. Add the following foreign entities:

Name Address Principal place of business
(city and state or country) 		Amount of contribution for lobbying activities Ownership percentage in client
Street Address
City State/Province Country
City
State Country
%

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

1 3 5
2 4 6

CONVICTIONS DISCLOSURE

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?

Lobbyist Name Description of Offense(s)